Staphylococcus aureus biofilms decrease osteoblast viability, inhibits osteogenic differentiation, and increases bone resorption in vitro

BMC Musculoskeletal Disorders

Joseph C Wenke¹  Christopher R Rathbone¹  Alex V Trevino¹  Ronald L Woodbury¹  Sharanda K Hardy¹  Brady J Hurtgen¹  Desiree R Romano¹  Catherine L Ward¹  Carlos J Sanchez¹ 

[1] Department of Extremity Trauma and Regenerative Medicine, United States Army Institute of Surgical Research, Ft. Sam Houston, San Antonio, TX, USA

关键词: Osteoprotegrin;    Receptor activator of NF-kB ligand;    Staphylococcus aureus;    Osteogenic differentiation;    Osteoblast;    Biofilm;   

Others  :  1130546
DOI  :  10.1186/1471-2474-14-187

 received in 2013-01-31, accepted in 2013-06-06,  发布年份 2013

【 摘 要 】

Background

Osteomyelitis is a severe and often debilitating disease characterized by inflammatory destruction of bone. Despite treatment, chronic infection often develops which is associated with increased rates of treatment failure, delayed osseous-union, and extremity amputation. Within affected bone, bacteria exist as biofilms, however the impact of biofilms on osteoblasts during disease are unknown. Herein, we evaluated the effect of S. aureus biofilms on osteoblast viability, osteogenic potential, and the expression of the pro-osteoclast factor, receptor activator of NF-kB ligand (RANK-L).

Methods

Osteoblasts were exposed to biofilm conditioned media (BCM) from clinical wound isolates of Staphylococcus aureus under normal growth and osteogenic conditions to assess cellular viability and osteoblast differentiation, respectively. Cell viability was evaluated using a live/dead assay and by quantifying total cellular DNA at days 0, 1, 3, 5, and 7. Apoptosis following treatment with BCM was measured by flow-cytometry using the annexin V-FITC/PI apoptosis kit. Osteogenic differentiation was assessed by measuring alkaline phosphatase activity and intracellular accumulation of calcium and osteocalcin for up to 21 days following exposure to BCM. Expression of genes involved in osteogenic differentiation and osteoclast regulation, were also evaluated by quantitative real-time PCR.

Results

BCM from clinical strains of S. aureus reduced osteoblast viability which was accompanied by an increase in apoptosis. Osteogenic differentiation was significantly inhibited following treatment with BCM as indicated by decreased alkaline phosphatase activity, decreased intracellular accumulation of calcium and inorganic phosphate, as well as reduced expression of transcription factors and genes involved in bone mineralization in viable cells. Importantly, exposure of osteoblasts to BCM resulted in up-regulated expression of RANK-L and increase in the RANK-L/OPG ratio compared to the untreated controls.

Conclusions

Together these studies suggest that soluble factors produced by S. aureus biofilms may contribute to bone loss during chronic osteomyelitis simultaneously by: (1) reducing osteoblast viability and osteogenic potential thereby limiting new bone growth and (2) promoting bone resorption through increased expression of RANK-L by osteoblasts. To our knowledge these are the first studies to demonstrate the impact of staphylococcal biofilms on osteoblast function, and provide an enhanced understanding of the pathogenic role of staphylococcal biofilms during osteomyelitis.

【 授权许可】

   
2013 Sanchez et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Lew DP, Waldvogel FA: Osteomyelitis. Lancet 2004, 364:369-379.
• [2]Conterno LO, da Silva Filho CR: Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev 2009, 3:CD004439.
• [3]Huh J, Stinner DJ, Burns TC, Hsu JR: Infectious complications and soft tissue injury contribute to late amputation after severe lower extremity trauma. J Trauma 2011, 71:S47-S51.
• [4]Costerton JW: Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin Orthop Relat Res 2005, 437:7-11.
• [5]Costerton JW, Stewart PS, Greenberg EP: Bacterial biofilms: a common cause of persistent infections. Science 1999, 284:1318-1322.
• [6]Costerton JW: Introduction to biofilm. Int J Antimicrob Agents 1999, 11:217-221. discussion 237–219
• [7]Hall-Stoodley L, Costerton JW, Stoodley P: Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004, 2:95-108.
• [8]Brady RA, Leid JG, Calhoun JH, Costerton JW, Shirtliff ME: Osteomyelitis and the role of biofilms in chronic infection. FEMS Immunol Med Microbiol 2008, 52:13-22.
• [9]Marrie TJ, Costerton JW: Mode of growth of bacterial pathogens in chronic polymicrobial human osteomyelitis. J Clin Microbiol 1985, 22:924-933.
• [10]Gristina AG, Oga M, Webb LX, Hobgood CD: Adherent bacterial colonization in the pathogenesis of osteomyelitis. Science 1985, 228:990-993.
• [11]Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW: Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J Am Dent Assoc 2009, 140:1259-1265.
• [12]Esteban J, Molina-Manso D, Spiliopoulou I, Cordero-Ampuero J, Fernandez-Roblas R, Foka A, Gomez-Barrena E: Biofilm development by clinical isolates of Staphylococcus spp. from retrieved orthopedic prostheses. Acta Orthop 2010, 81:674-679.
• [13]O’Neill E, Pozzi C, Houston P, Smyth D, Humphreys H, Robinson DA, O’Gara JP: Association between methicillin susceptibility and biofilm regulation in Staphylococcus aureus isolates from device-related infections. J Clin Microbiol 2007, 45:1379-1388.
• [14]Sanchez CJ Jr, Mende K, Beckius ML, Akers KS, Romano DR, Wenke JC, Murray CK: Biofilm formation by clinical isolates and the implications in chronic infections. BMC Infect Dis 2013, 13:47. BioMed Central Full Text
• [15]Palmer M, Costerton W, Sewecke J, Altman D: Molecular techniques to detect biofilm bacteria in long bone nonunion: a case report. Clin Orthop Relat Res 2011, 469:3037-3042.
• [16]Altman DT, AltmanT GT, Sewecke JJ, Gause TM, Costerton WJ: Can We Trust Intraoperative Culture Results in Nonunions?. San Antonio, TX: Orthopaedic Trauma Association; 2011. 12–15 October 2011
• [17]Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998, 95:3597-3602.
• [18]Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345-357.
• [19]Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
• [20]Marriott I: Osteoblast responses to bacterial pathogens: a previously unappreciated role for bone-forming cells in host defense and disease progression. Immunol Res 2004, 30:291-308.
• [21]Montanaro L, Testoni F, Poggi A, Visai L, Speziale P, Arciola CR: Emerging pathogenetic mechanisms of the implant-related osteomyelitis by Staphylococcus aureus. Int J Artif Organs 2011, 34:781-788.
• [22]Boyce BF, Xing L: Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008, 473:139-146.
• [23]Claro T, Widaa A, O’Seaghdha M, Miajlovic H, Foster TJ, O’Brien FJ, Kerrigan SW: Staphylococcus aureus protein A binds to osteoblasts and triggers signals that weaken bone in osteomyelitis. PLoS One 2011, 6:e18748.
• [24]Widaa A, Claro T, Foster TJ, O’Brien FJ, Kerrigan SW: Staphylococcus aureus Protein A Plays a Critical Role in Mediating Bone Destruction and Bone Loss in Osteomyelitis. PLoS One 2012, 7:e40586.
• [25]Smeltzer MS, Thomas JR, Hickmon SG, Skinner RA, Nelson CL, Griffith D, Parr TR Jr, Evans RP: Characterization of a rabbit model of staphylococcal osteomyelitis. J Orthop Res 1997, 15:414-421.
• [26]Weiss EC, Zielinska A, Beenken KE, Spencer HJ, Daily SJ, Smeltzer MS: Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo. Antimicrob Agents Chemother 2009, 53:4096-4102.
• [27]Secor PR, James GA, Fleckman P, Olerud JE, McInnerney K, Stewart PS: Staphylococcus aureus Biofilm and Planktonic cultures differentially impact gene expression, mapk phosphorylation, and cytokine production in human keratinocytes. BMC Microbiol 2011, 11:143. BioMed Central Full Text
• [28]Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF, Melton DM, Beachey EH: Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol 1985, 22:996-1006.
• [29]Shevchenko A, Wilm M, Vorm O, Jensen ON, Podtelejnikov AV, Neubauer G, Mortensen P, Mann M: A strategy for identifying gel-separated proteins in sequence databases by MS alone. Biochem Soc Trans 1996, 24:893-896.
• [30]van Engeland M, Ramaekers FC, Schutte B, Reutelingsperger CP: A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 1996, 24:131-139.
• [31]Xiao Y, Zhong Y, Greene W, Dong F, Zhong G: Chlamydia trachomatis infection inhibits both Bax and Bak activation induced by staurosporine. Infect Immun 2004, 72:5470-5474.
• [32]Stephens AS, Stephens SR, Morrison NA: Internal control genes for quantitative RT-PCR expression analysis in mouse osteoblasts, osteoclasts and macrophages. BMC Res Notes 2011, 4:410. BioMed Central Full Text
• [33]Arciola CR, Hansch GM, Visai L, Testoni F, Maurer S, Campoccia D, Selan L, Montanaro L: Interactions of staphylococci with osteoblasts and phagocytes in the pathogenesis of implant-associated osteomyelitis. Int J Artif Organs 2012, 10:713-726.
• [34]Claro T, Widaa A, McDonnell C, Foster TJ, O’Brien FJ, Kerrigan SW: Staphylococcus aureus protein A binding to osteoblast tumour necrosis factor receptor 1 results in activation of nuclear factor kappa B and release of interleukin-6 in bone infection. Microbiology 2013, 159:147-154.
• [35]Ning RD, Zhang XL, Li QT, Guo XK: The effect of Staphylococcus aureus on apoptosis of cultured human osteoblasts. Orthop Surg 2011, 3:199-204.
• [36]Percival SL, Hill KE, Malic S, Thomas DW, Williams DW: Antimicrobial tolerance and the significance of persister cells in recalcitrant chronic wound biofilms. Wound Repair Regen 2011, 19:1-9.
• [37]Thomson CH: Biofilms: do they affect wound healing? Int Wound J 2011, 8:63-67.
• [38]Wolcott R, Dowd S: The role of biofilms: are we hitting the right target? Plast Reconstr Surg 2011, 127(Suppl 1):28S-35S.
• [39]Kirker KR, James GA, Fleckman P, Olerud JE, Stewart PS: Differential effects of planktonic and biofilm MRSA on human fibroblasts. Wound Repair Regen 2012, 20:253-261.
• [40]James GA, Swogger E, Wolcott R, Pulcini E, Secor P, Sestrich J, Costerton JW, Stewart PS: Biofilms in chronic wounds. Wound Repair Regen 2008, 16:37-44.
• [41]Stephens P, Wall IB, Wilson MJ, Hill KE, Davies CE, Hill CM, Harding KG, Thomas DW: Anaerobic cocci populating the deep tissues of chronic wounds impair cellular wound healing responses in vitro. Br J Dermatol 2003, 148:456-466.
• [42]Young AB, Cooley ID, Chauhan VS, Marriott I: Causative agents of osteomyelitis induce death domain-containing TNF-related apoptosis-inducing ligand receptor expression on osteoblasts. Bone 2011, 48:857-863.
• [43]McCall SH, Sahraei M, Young AB, Worley CS, Duncan JA, Ting JP, Marriott I: Osteoblasts express NLRP3, a nucleotide-binding domain and leucine-rich repeat region containing receptor implicated in bacterially induced cell death. J Bone Miner Res 2008, 23:30-40.
• [44]Thomas VC, Hancock LE: Suicide and fratricide in bacterial biofilms. Int J Artif Organs 2009, 32:537-544.
• [45]Bayles KW: The biological role of death and lysis in biofilm development. Nat Rev Microbiol 2007, 5:721-726.
• [46]DeLeo FR, Diep BA, Otto M: Host defense and pathogenesis in Staphylococcus aureus infections. Infect Dis Clin North Am 2009, 23:17-34.
• [47]Walev I, Martin E, Jonas D, Mohamadzadeh M, Muller-Klieser W, Kunz L, Bhakdi S: Staphylococcal alpha-toxin kills human keratinocytes by permeabilizing the plasma membrane for monovalent ions. Infect Immun 1993, 61:4972-4979.
• [48]Walev I, Palmer M, Martin E, Jonas D, Weller U, Hohn-Bentz H, Husmann M, Bhakdi S: Recovery of human fibroblasts from attack by the pore-forming alpha-toxin of Staphylococcus aureus. Microb Pathog 1994, 17:187-201.
• [49]Craven RR, Gao X, Allen IC, Gris D, Bubeck Wardenburg J, McElvania-Tekippe E, Ting JP, Duncan JA: Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS One 2009, 4:e7446.
• [50]Smagur J, Guzik K, Magiera L, Bzowska M, Gruca M, Thogersen IB, Enghild JJ, Potempa J: A new pathway of staphylococcal pathogenesis: apoptosis-like death induced by Staphopain B in human neutrophils and monocytes. J Innate Immun 2009, 1:98-108.
• [51]Smagur J, Guzik K, Bzowska M, Kuzak M, Zarebski M, Kantyka T, Walski M, Gajkowska B, Potempa J: Staphylococcal cysteine protease staphopain B (SspB) induces rapid engulfment of human neutrophils and monocytes by macrophages. Biol Chem 2009, 390:361-371.
• [52]Komori T: Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res 2010, 339:189-195.
• [53]Komori T: Regulation of osteoblast differentiation by Runx2. Adv Exp Med Biol 2010, 658:43-49.
• [54]Hofbauer LC, Kuhne CA, Viereck V: The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 2004, 4:268-275.